EQS-News

Anniversary of BRAIN Biotech AG: 30 years for a bio-based future

EQS-News: BRAIN Biotech AG / Key word(s): Miscellaneous Anniversary of BRAIN Biotech AG: 30 years for a bio-based future 19.06.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Anniversary of BRAIN Biotech AG: 30 years for a bio-based future

Zwingenberg, Germany, June 19, 2023 – BRAIN Biotech, a leading European provider of bio-based products and solutions for industry, celebrates its 30th anniversary. Founded in the 1990s, the company has always been a pioneer in industrial biotechnology, developing innovative solutions for more sustainable industrial products and processes.

“For now 30 years, our highly qualified experts at BRAIN Biotech have been committed using nature as a role model to develop solutions and products for sustainable industrial production,” said CEO Adriaan Moelker at a ceremony attended by shareholders, customers, employees and guests from business, associations and local politics. “The concept of the circular economy has built the basis of our business model from the very beginning, and today I strongly believe that we can all be very proud of what BRAIN has achieved over the last three decades,” Moelker continued.

BRAIN Biotech was founded in 1993 as a technology spin-off by a team of scientists from the University of Darmstadt. The discovery and characterization of specialized microbial strains and enzymes, the search for bioactive natural products and protein engineering formed the basis of the company's activities from the very beginning. Accelerated by the IPO on the Frankfurt Stock Exchange in 2016 and several acquisitions, the company developed over the years into a provider of integrated solutions in the field of industrial biotechnology and expanded its enzyme product business. Today, BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group with fermentation facilities in the UK and additional production sites in continental Europe and the US. In addition to the product business with specialty enzymes, the group offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening.